Sirolimus Rx purity and testing: what buyers should verify

Last updated 2026-07-27

What does "purity and testing" actually mean for sirolimus?

Two very different products get called "sirolimus," and buyers routinely conflate them. One is Rapamune, the FDA-approved brand (and its generic equivalents), manufactured under strict batch-release testing required for any approved drug. The other is compounded sirolimus, made to order by a compounding pharmacy for off-label, low-dose, intermittent longevity protocols that no drug company sells a ready-made product for. FDA-approved manufacturing means every batch is tested against a validated specification before it ships: identity, potency, purity, dissolution, sterility where relevant. That's baked into the New Drug Application process ^[1]. Compounded sirolimus doesn't go through that. It's made under a different legal framework (Section 503A or 503B of the Food, Drug, and Cosmetic Act), and testing requirements are lighter and less standardized ^[2]. That doesn't mean compounded sirolimus is unsafe by default. It means the burden of verifying quality shifts from "the FDA already checked" to "you need to ask the pharmacy directly." Sirolimus and rapamycin are the same molecule, just two names from two eras of the drug's history (rapamycin was the original name from the Rapa Nui soil sample it was isolated from; sirolimus is the USAN/INN generic name used on the label). Nothing about purity concerns changes based on which name you see on the paperwork. Sirolimus Rx operates as a provider-reviewed pathway that connects patients to a clinician for an off-label evaluation and to a licensed pharmacy for fulfillment. It does not compound or manufacture anything itself, so purity and testing questions are really questions for the fulfilling pharmacy, and a legitimate provider-reviewed service should be able to tell you which pharmacy that is and what their quality documentation looks like.

Is compounded sirolimus regulated the same way as FDA-approved sirolimus?

No. FDA-approved sirolimus (Rapamune, approved in 1999 for kidney transplant rejection prophylaxis) goes through the full NDA review and post-approval manufacturing oversight under 21 CFR Part 314 ^[1][3]. Compounded sirolimus is regulated under a separate, lighter framework. Section 503A compounding pharmacies prepare patient-specific prescriptions and are primarily overseen by state boards of pharmacy, with FDA maintaining a smaller role. Section 503B outsourcing facilities can compound in larger batches without a patient-specific prescription first, register with FDA, and are subject to current good manufacturing practice (cGMP) inspection, which is closer to (but still not identical to) full drug manufacturing standards ^[2]. FDA has been explicit that compounded drugs "are not FDA-approved," meaning "FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed" ^[4]. That single sentence is the whole regulatory gap in one line. For a drug like sirolimus, which has a genuinely narrow therapeutic window and requires blood monitoring even in its approved use ^[5], that gap matters more than it would for a compounded topical vitamin cream. Practically: ask which section your pharmacy operates under. A 503B outsourcing facility with cGMP registration and third-party testing is a meaningfully stronger quality signal than an unnamed 503A pharmacy that won't discuss its sourcing.

What is a certificate of analysis (COA) and should sirolimus come with one?

A certificate of analysis is a lab document showing the actual tested results for a specific batch: identity confirmation, potency (percent of labeled active ingredient), and often testing for contaminants like heavy metals or microbial load. For raw active pharmaceutical ingredient (API) used in compounding, USP monograph testing is the relevant standard. A reputable compounding pharmacy should be able to produce, or at least describe, the COA for the sirolimus API it sources, and should be testing (or have its supplier test) against the USP Sirolimus monograph, which specifies acceptable purity ranges and identifies impurity limits ^[6]. If a pharmacy can't tell you where its API comes from or won't discuss potency testing, that's a real red flag, not a paperwork technicality. This matters more for sirolimus than for many compounded drugs because the therapeutic and toxic doses aren't far apart. A capsule that's 20% under-potent could mean months of an ineffective off-label protocol; one that's 20% over-potent, combined with sirolimus's long half-life (roughly 57 to 63 hours in transplant patients) ^[5], could compound toxicity before blood levels even show it. Regular monitoring closes part of that gap, which is why Sirolimus Rx and blood work matters as much as the capsule itself. Ask directly: "What USP chapter do you compound under, and can I see a COA for this batch or lot?" A pharmacy with nothing to hide will answer in one email.

What do USP <795> and USP <797> mean for a compounding pharmacy?

USP <795> and <797> are United States Pharmacopeia standards that govern how compounding pharmacies prepare non-sterile and sterile drugs, respectively. Sirolimus for oral use is typically non-sterile compounding, so <795> is the relevant chapter, covering things like environmental controls, equipment cleaning, ingredient verification, and stability/beyond-use dating . These aren't optional best practices. State boards of pharmacy generally require accredited pharmacies to follow current USP chapters, and many states inspect against them. A pharmacy that mentions USP <795> compliance by name, unprompted, is signaling it takes the standard seriously; one that has never heard of it should concern you. Beyond-use dating (BUD) is worth asking about specifically. Compounded oral capsules without stability data typically get a default BUD far shorter than a manufactured drug's multi-year shelf life, sometimes 6 months or less depending on formulation and USP <795> default limits . If your capsules arrive with no expiration information at all, ask why.

How do I know the compounded sirolimus I'm getting has the right dose in every capsule?

You mostly can't verify this yourself at home; there's no consumer-grade test for milligram-level potency in a capsule. What you can do is ask the pharmacy about their content uniformity testing, which measures whether each capsule in a batch actually contains the labeled dose within an accepted tolerance. Content uniformity is a known failure point in compounding generally. FDA's compounding risk alerts and inspection findings over the years have repeatedly flagged potency variability as a real-world problem in some compounding pharmacies, not a theoretical one ^[2][4]. For a drug dosed intermittently at low weekly amounts (the common off-label longevity protocols use once-weekly dosing in the roughly 1 to 6 mg range, though no clinical guideline endorses a specific longevity dose), a 30% swing in actual content is a much bigger deal proportionally than it would be with a drug dosed daily at high milligram amounts. The practical answer: use blood level monitoring (trough sirolimus levels via a standard immunoassay or LC-MS/MS) as your real-world potency check, not the label. If your levels come back wildly inconsistent with your dose across two or three tests using the same pharmacy's product, that's a signal worth escalating, either to a different pharmacy or to your prescriber. See Sirolimus Rx dosage calculator for how weight-based and protocol-based dosing gets estimated before blood work confirms it.

Does purity affect the immunosuppression, mouth ulcer, or metabolic side-effect risk?

Yes, in the sense that an under- or over-potent capsule shifts you along the same dose-response curve that governs sirolimus's known risks, even at low intermittent doses. Purity problems don't create new side effects; they make the existing ones less predictable. Sirolimus's core mechanism, mTOR inhibition, is also why it's an approved immunosuppressant. Even at low, intermittent, off-label longevity doses, some degree of immune modulation is expected, and case reports and small studies of intermittent dosing describe increased infection susceptibility as a plausible risk, though the size of that risk at low intermittent doses (versus the high continuous transplant doses) hasn't been established in controlled human trials . Mouth ulcers (stomatitis) are one of the most consistently reported side effects of sirolimus at any dose, including in the original transplant trials, where oral ulceration was reported in a meaningful minority of patients ^[5]. Metabolic effects, including elevated triglycerides, elevated LDL cholesterol, and in some cases new or worsened hyperglycemia, are also documented in the FDA label for Rapamune and are mechanistically expected from mTOR inhibition's effect on lipid metabolism ^[5]. None of this is exotic or hidden; it's on the FDA label for the approved indication. What's missing is data on how these risks scale down (or don't) at the low, once-weekly intermittent doses used off-label for longevity, because no completed human trial has systematically tracked that. For a fuller rundown of what's tracked long-term, see Sirolimus Rx long term side effects and Sirolimus Rx contraindications for who shouldn't be taking this at all.

Is there any independent, third-party testing for sirolimus compounding pharmacies?

Some, but it's inconsistent across the industry. There's no single national database where you can look up a compounding pharmacy's sirolimus batch test results the way you might check a lot number against FDA's approved-drug adverse event database. Third-party accreditation bodies exist for compounding pharmacies, including PCAB (Pharmacy Compounding Accreditation Board) accreditation, which reviews facilities against USP standards and quality systems. Accreditation is voluntary, not required by every state, but a pharmacy that holds it has been through an external audit process rather than only self-attesting. Some outsourcing facilities registered under 503B also publish or provide COAs per batch on request, since they're producing at larger scale and are subject to FDA registration and inspection ^[2]. If you're comparing two potential sources, "do you hold PCAB accreditation or 503B registration, and will you send me a current COA" is a fair, answerable question, and a pharmacy's willingness (or refusal) to answer it tells you a lot on its own.

What should I actually ask a pharmacy or provider before ordering sirolimus?

Here's a short list worth going through before you send payment, not after: 1. Which pharmacy compounds this, and is it 503A or 503B? 2. Can I see a current certificate of analysis for the API or batch? 3. Do you compound under USP <795>, and what's the beyond-use date on my capsules? 4. Is the pharmacy PCAB accredited or does it hold any third-party quality certification? 5. What baseline labs (lipid panel, CBC, fasting glucose, kidney function) happen before the first prescription, and what's the monitoring schedule after? 6. Who reviews my medical history for contraindications (organ transplant status, active infection, pregnancy, certain drug interactions)? 7. What happens if my blood levels come back outside expected range? A provider-reviewed model, where a licensed clinician evaluates your history and orders through a named, licensed pharmacy, is a meaningfully different risk profile than an unnamed website selling capsules with no clinical oversight and no pharmacy disclosed. Sirolimus Rx's role in that chain is the provider-review and pharmacy-matching step; it doesn't compound the drug itself, and any purity claim should be traceable back to the specific dispensing pharmacy, not to the referral service.

Does FDA approval of Rapamune mean the longevity dosing is also approved?

No, and this is the single most important thing to understand before any purity conversation matters at all. Rapamune is FDA-approved only for prophylaxis of organ rejection in kidney transplant patients aged 13 and older, dosed daily and monitored closely by transplant teams ^[5]. Fyarro (a nanoparticle albumin-bound sirolimus formulation) is approved for a rare cancer, malignant perivascular epithelioid cell tumor, and Hyftor is a topical rapamycin approved for facial angiofibromas in tuberous sclerosis complex . None of these approvals cover low-dose, intermittent, weekly dosing for aging, lifespan extension, or "longevity." That use is entirely off-label. The strongest evidence for a lifespan effect comes from mice: the National Institute on Aging's Interventions Testing Program (ITP) found rapamycin extended median lifespan in genetically heterogeneous mice at multiple independent test sites, including sizable effects in a 2009 report and confirmed dose-response effects in later years, with some cohorts showing roughly a 9 to 14% increase in median lifespan in females and somewhat different magnitudes in males depending on dose and start age . That is genuinely strong animal data, replicated across sites and years, which is unusual and noteworthy in aging research. But there is no completed human lifespan trial for rapamycin. None. Human data on "longevity dosing" comes from small studies of surrogate markers, immune function readouts, and self-reported outcomes, not from a randomized trial measuring whether people who take it live longer. Anyone selling you rapamycin for longevity should say this plainly, and if they don't, that's worth noticing. For the actual state of the human evidence, read Sirolimus Rx results what the research shows and treat anecdote-heavy marketing with the skepticism covered in Sirolimus Rx before and after claims.

How does compounded sirolimus purity compare across sourcing options?

Frequently asked questions

Is compounded sirolimus FDA-approved?

No. Only Rapamune (and its approved generics), Fyarro, and Hyftor are FDA-approved sirolimus/rapamycin products, for transplant rejection prophylaxis, a rare cancer, and facial angiofibromas respectively. Compounded sirolimus made for off-label longevity dosing is not FDA-approved and is not independently batch-tested by FDA before it reaches you; quality depends on the compounding pharmacy.

What's the difference between sirolimus and rapamycin?

Nothing pharmacologically. Rapamycin was the original name given when the compound was isolated from soil bacteria on Easter Island (Rapa Nui); sirolimus is the generic (USAN/INN) name used once it became a marketed drug. You'll see both terms in longevity discussions and scientific papers referring to the identical molecule.

Can I ask a compounding pharmacy for a certificate of analysis?

Yes, and you should. A COA shows tested identity, potency, and purity results for the API or batch used. A pharmacy unwilling to provide or discuss one is a meaningful red flag; a legitimate 503A or 503B pharmacy compounding sirolimus should be able to speak to its sourcing and testing without hesitation.

Does USP <795> guarantee my sirolimus capsules are pure?

No single standard guarantees purity, but USP <795> compliance is a strong baseline signal. It governs non-sterile compounding practices including ingredient verification, equipment cleaning, and beyond-use dating. Ask whether your pharmacy compounds under current USP <795>, and treat a confident, specific answer as more reassuring than a vague one.

Has any human trial shown rapamycin extends lifespan in people?

No completed human trial has measured lifespan extension from rapamycin. The strongest evidence is in mice, via the NIA's Interventions Testing Program, which found consistent median lifespan extension across multiple independent labs. Human data covers surrogate markers like immune response and small safety studies, not survival.

What side effects should I expect from low-dose intermittent sirolimus?

Documented risks from FDA labeling and clinical use, even though most longevity dosing is off-label and lower-dose, include mouth ulcers (stomatitis), elevated triglycerides and LDL cholesterol, increased infection susceptibility from immune modulation, and in some cases impaired wound healing or new hyperglycemia. How these risks scale at low intermittent doses hasn't been studied in a large controlled trial.

Is 503A or 503B compounding better for sirolimus purity?

503B outsourcing facilities register with FDA and undergo cGMP-adjacent inspection, and often provide batch COAs on request, giving somewhat more verifiable oversight. 503A pharmacies are overseen primarily by state boards and compound per prescription; quality varies more by individual pharmacy, so ask about USP <795> compliance and PCAB accreditation directly.

How do I know if my sirolimus dose is actually being absorbed correctly?

Blood trough level testing is the practical check, since there's no home test for capsule potency. If your measured blood levels don't track consistently with your prescribed dose across two or three tests from the same pharmacy source, raise it with your prescriber; it may point to a content uniformity issue rather than something you're doing wrong.

What is PCAB accreditation and does it matter for sirolimus?

PCAB (Pharmacy Compounding Accreditation Board) accreditation is a voluntary third-party audit of a compounding pharmacy against USP and quality-system standards. It's not required by every state, but it is a genuine external check rather than self-attestation, and it's a reasonable question to ask any pharmacy compounding sirolimus for you.

Why does purity matter more for sirolimus than for many other compounded drugs?

Sirolimus has a narrow therapeutic window and a long half-life (roughly 57 to 63 hours), so under- or over-potent capsules can meaningfully shift efficacy or toxicity before blood testing catches it. It also requires monitoring even in its FDA-approved transplant use, which is a signal of how much precision the drug demands generally.

Can rapamycin purity issues cause immunosuppression I don't expect?

An over-potent capsule could push you further along sirolimus's known immunosuppressive dose-response curve than intended, since the drug's core mechanism, mTOR inhibition, is also what makes it an effective transplant immunosuppressant at higher doses. This is a reason to prioritize tested, monitored sourcing over the cheapest available option.

Does Sirolimus manufacture or compound the sirolimus itself?

No. Sirolimus Rx is a provider-reviewed pathway connecting patients to a clinician evaluation and to a licensed, named fulfilling pharmacy; it does not compound, manufacture, or test the drug itself. Purity and testing questions should be directed to, and are the responsibility of, the specific dispensing pharmacy in that chain.

What's the beyond-use date on compounded sirolimus and why does it matter?

Beyond-use date (BUD) is the compounding equivalent of an expiration date, often far shorter than a manufactured drug's shelf life (sometimes 6 months or less under default USP <795> limits) unless stability data supports longer dating. Capsules with no BUD listed, or an implausibly long one with no explanation, are worth questioning before use.

Sources

1. FDA, New Drug Application (NDA) process overview: FDA-approved drugs undergo batch-release manufacturing oversight under the NDA process
2. eCFR, 21 CFR Part 314: Federal regulation governing FDA approval and oversight of new drug applications
3. USP, Sirolimus monograph reference (USP-NF): USP monograph standards apply to sirolimus API purity and potency testing in compounding
4. USP General Chapter <795>, Pharmaceutical Compounding - Nonsterile Preparations: USP <795> governs non-sterile compounding practices including beyond-use dating and ingredient verification
5. Harrison et al., "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice," Nature 460:392-395 (2009), PMID 19587680: Rapamycin extended median lifespan in genetically heterogeneous mice across multiple independent test sites
6. Miller et al., "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction," Aging Cell 13(3):468-477 (2014), PMID 24341993: NIA ITP has confirmed rapamycin's lifespan-extension effect across repeated cohorts and dose levels in mice, with no completed human lifespan trial to date